• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT IRELAND DIAGNOSTICS DIVISION LONGFORD ARCHITECT TOTAL T3; TOTAL TRIIODOTHYRONINE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT IRELAND DIAGNOSTICS DIVISION LONGFORD ARCHITECT TOTAL T3; TOTAL TRIIODOTHYRONINE Back to Search Results
Model Number 7K64-35
Medical Device Problem Code Low Test Results (2458)
Health Effect - Clinical Code No Patient Involvement (2645)
Date of Event 05/28/2020
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
Correction/removal number: 3005094123-10/22/18-001-c.Product correction letters were issued on 12oct2018 to all architect total t3 (tt3) and free t3 (ft3) customers, using the i1000sr, i2000, or i2000sr instruments and who received one of the impacted lots.The letter instructed the customers to prevent this interaction by either separating the architect ft3 and/or architect tt3 assays by running these tests on different instruments from the following assays [architect tsh, architect t-uptake, architect hiv ag/ab combo, architect cortisol, architect lh, architect progrp, architect rhtlv-i/ii, architect total psa, architect afp, and architect free psa, architect 25-oh vitamin d], or by performing daily maintenance on the instrument prior to performing batch testing for all ft3 and/or tt3 samples.The mechanism of carryover involves carryover of poly-l-lysine (pll) from other assays into the conjugate dispense step in the ft3 and tt3 assays through adherence of the pipetting probe.
 
Event or Problem Description
The customer reported a falsely decreased architect total t3 result on one patient while processing with the reagent lot 13003ui00.Results provided: (b)(6) 2020 initial = < 40 ng/dl, repeat = 60 ng/dl.No impact to patient management was reported.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ARCHITECT TOTAL T3
Common Device Name
TOTAL TRIIODOTHYRONINE
Manufacturer (Section D)
ABBOTT IRELAND DIAGNOSTICS DIVISION LONGFORD
lisnamuck
co. longford
longford NA
EI  NA
MDR Report Key10164860
Report Number3005094123-2020-00127
Device Sequence Number11656124
Product Code CDP
UDI-Device Identifier00380740105945
UDI-Public00380740105945
Combination Product (Y/N)N
Initial Reporter CountryIN
PMA/510(K) Number
EXEMPT
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source foreign,health professional
Initial Reporter Occupation Physician
Remedial Action Notification
Type of Report Initial
Report Date (Section B) 06/17/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date01/20/2021
Device Model Number7K64-35
Device Catalogue Number07K64-35
Device Lot Number13003UI00
Was Device Available for Evaluation? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 06/10/2020
Initial Report FDA Received Date06/17/2020
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
If action reported to FDA under 21 USC 360i(g), list
FDA-assigned Recall Number or include a statement
3005094123-10/22/18-001
Patient Sequence Number1
-
-